Dr. Ken Kato, National Cancer Center Hospital, Japan
Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology π₯. Holding both an M.D. and a Ph.D. from prestigious institutions π, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer π§¬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment π. Dr. Kato is also an active member of several professional societies worldwide π.
Publication profile
Scopus
Education
Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 π.
Research Focus
Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies π§¬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance π. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes π. Dr. Katoβs research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy π.
Publication Top Notes
- A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 π
, Cited by: 0 π
- ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453β463 π
, Cited by: 21 π
- Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863β870 π
, Cited by: 3 π
- Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 π
, Cited by: 41 π¬
- Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002β1007 π
, Cited by: 24 π§¬
- Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366β374 π
, Cited by: 7 π
- A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183β188 π
, Cited by: 30 π©Ί
- Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522β528 π
, Cited by: 26 π
- Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588β2595 π
, Cited by: 33 π§ͺ
- Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42β49 π
, Cited by: 31 π©Ή